| Name | Immupharma |
|---|---|
| Epic | IMM |
| Isin | GB0033711010 |
| Index | AIM100 AIM350 |
| Industry | Pharmaceuticals & Biotechnology |
| Latest share price | 3.35p | Net gearing | n/a |
|---|---|---|---|
| Market capitalisation | £13.95 | Debt ratio | n/a |
| Shares in issue | 416.44 | Debt-to-equity ratio | n/a |
| P/E ratio | n/a | Assets / equity ratio | n/a |
| Total dividends per share | n/a | Price to book value | n/a |
| Dividend yield | n/a | ROCE | -503.78 |
| Dividend cover | n/a | EPS growth | n/a |
| Earning per share | -0.81 | 52-week high / low | 0.85p / 3.75p |
| Type | Ex-date | Pay-date | Net-dividend |
|---|---|---|---|
| No dividends declared | |||
| Company name | Immupharma |
|---|---|
| Address | One Bartholomew Close, London, United Kingdom, EC1A 7BL |
| Telephone | +44 20 7152 4080 |
| Website | http://www.immupharma.co.uk/ |
| Director | Position |
|---|---|
| Mr Timothy Paul McCarthy | CEO |
| Ms Lisa Baderoon | Non-Executive Director |
| Mr Sébastien Goudreau | Non-Executive Director |
| Dr. Laurence Reilly | Senior Independent Non-Executive Director |
| Dr Tim Franklin | Chief Operating Officer |
| Assets £ (m) | 2023 | 2022 | 2021 |
|---|---|---|---|
| Reporting date | 31/12/23 | 31/12/22 | 31/12/21 |
| Intangible asssets and goodwill | 0.45 | 0.47 | 0.48 |
| Investments and other non-current assets | n/a | n/a | n/a |
| Total non-current assets | 1.38 | 1.64 | 2.65 |
| Inventory / work in progress | n/a | n/a | n/a |
| Trade and other receivables | 0.47 | 0.72 | 0.43 |
| Cash and equivalents | 0.21 | 0.67 | 1.65 |
| Other current assets and asset held for resale | 0.67 | 0.95 | 1.27 |
| Total of all assets | 2.72 | 3.98 | 6 |
| Liabilities £ (m) | 2023 | 2022 | 2021 |
|---|---|---|---|
| Short term liabilities | 1.66 | 1.45 | 1.58 |
| Long term liabilities | n/a | n/a | n/a |
| Other liabilites / pension etc | n/a | n/a | n/a |
| Total of all liabilities | 1.67 | 1.45 | 1.58 |
| Net assets £ (m) | 2023 | 2022 | 2021 |
|---|---|---|---|
| Net assets | 1.06 | 2.52 | 4.41 |
| Equity £ (m) | 2023 | 2022 | 2021 |
|---|---|---|---|
| Share capital | 29.81 | 28.98 | 28.5 |
| Minority interests | n/a | n/a | n/a |
| Retained earnings | -64.08 | -61.12 | -56.58 |
| Share premium account | 29.32 | 28.79 | 27.24 |
| Total equity | 1.06 | 2.52 | 4.41 |
| Income £ (m) | 2023 | 2022 | 2021 |
|---|---|---|---|
| Turnover | n/a | n/a | n/a |
| Operating profit | -3.06 | -3.03 | -6.59 |
| Pre-tax profit | -3.42 | -4.46 | -8.94 |